Published in Ann Oncol on August 05, 2011
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 0.99
Tumor lymphangiogenesis as a potential therapeutic target. J Oncol (2012) 0.97
Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets (2012) 0.97
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol (2012) 0.93
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem (2012) 0.87
Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) (2012) 0.81
The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem (2014) 0.80
Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study. PLoS One (2014) 0.78
Anti-angiogenesis in prostate cancer: knocked down but not out. Asian J Androl (2014) 0.77
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis (2016) 0.76
A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. Clin Genitourin Cancer (2014) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol (2009) 2.27
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst (2003) 2.16
Molecular markers and death from prostate cancer. Ann Intern Med (2009) 2.15
Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol (2009) 2.01
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71
cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene (2007) 1.58
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Molecular pathway for cancer metastasis to bone. J Biol Chem (2003) 1.47
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer (2009) 1.45
Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res (2008) 1.38
A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res (2004) 1.36
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36
Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer (2006) 1.33
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res (2008) 1.22
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res (2009) 1.20
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res (2001) 1.18
Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res (2005) 1.17
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett (2008) 1.00
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol (2007) 0.96
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate (2005) 0.95
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Genetic enhancement of learning and memory in mice. Nature (1999) 8.06
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999) 6.21
Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science (1999) 5.98
Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol (2001) 4.38
Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia (2001) 4.22
Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron (2001) 3.91
Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. Proc Natl Acad Sci U S A (1999) 3.90
PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization. Cell (1998) 3.79
Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes. Nat Genet (2000) 3.79
Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections. Proc Natl Acad Sci U S A (2000) 3.46
Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway. Cell (2001) 3.44
Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci U S A (2000) 3.41
Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 3.35
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
A family of peptidoglycan recognition proteins in the fruit fly Drosophila melanogaster. Proc Natl Acad Sci U S A (2000) 3.08
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet (2001) 2.85
Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 2.83
A peptidoglycan recognition protein in innate immunity conserved from insects to humans. Proc Natl Acad Sci U S A (1998) 2.81
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer (2009) 2.52
Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst (1997) 2.51
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med (1995) 2.50
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene (1997) 2.44
A new ultrasound instrument for in vivo microimaging of mice. Ultrasound Med Biol (2002) 2.34
Epidemiological link between exposure to poultry and all influenza A(H7N9) confirmed cases in Huzhou city, China, March to May 2013. Euro Surveill (2013) 2.34
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci U S A (1998) 2.28
Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology (1999) 2.16
Sarcomatoid renal cell carcinoma. A treatable entity. Cancer (1987) 2.12
Modulation of folding pathways of exported proteins by the leader sequence. Science (1988) 2.10
The growing teratoma syndrome. Cancer (1982) 2.09
Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab (2000) 2.09
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2010) 2.06
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2011) 2.05
Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res (1997) 2.02
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol (1983) 2.01
Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol (1991) 2.00
Mammalian peptidoglycan recognition protein binds peptidoglycan with high affinity, is expressed in neutrophils, and inhibits bacterial growth. J Biol Chem (2000) 1.99
Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis (2001) 1.96
The cytoplasmic domain of FtsK protein is required for resolution of chromosome dimers. Mol Microbiol (1999) 1.95
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology (2004) 1.92
Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer (1999) 1.90
Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer (1987) 1.90
Harvesting the genome's bounty: integrative genomics. Cold Spring Harb Symp Quant Biol (2003) 1.84
Visual attention to the periphery is enhanced in congenitally deaf individuals. J Neurosci (2000) 1.83
Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens (1998) 1.83
A humoral stress response in Drosophila. Curr Biol (2001) 1.82
Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A (1993) 1.82
The Drosophila caspase DRONC cleaves following glutamate or aspartate and is regulated by DIAP1, HID, and GRIM. J Biol Chem (2000) 1.81
Reduced warfarin binding of albumin variants. Science (1977) 1.73
DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem (1990) 1.73
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol (2000) 1.67
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia (2008) 1.67
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res (2001) 1.66
Impact of early deafness and early exposure to sign language on the cerebral organization for motion processing. J Neurosci (2001) 1.66
Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation (2000) 1.65
Three-dimensional dental model analysis of treatment outcomes for protrusive maxillary dentition: comparison of headgear, miniscrew, and miniplate skeletal anchorage. Am J Orthod Dentofacial Orthop (2008) 1.64
Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships. Toxicol Appl Pharmacol (1997) 1.61
Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol (1997) 1.59
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res (2000) 1.57
Flk-1 as a target for tumor growth inhibition. Cancer Res (1996) 1.56
Risk and predictors for pregnancy-related complications in women with heart disease. Circulation (1997) 1.56
Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia (2001) 1.56
Linkage of structure at the proximal femur to chromosomes 3, 7, 8, and 19. J Bone Miner Res (2003) 1.55
A cloning method to identify caspases and their regulators in yeast: identification of Drosophila IAP1 as an inhibitor of the Drosophila caspase DCP-1. Proc Natl Acad Sci U S A (1999) 1.55
Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med (1986) 1.55
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost (2013) 1.50
Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000. Acta Paediatr (2002) 1.50
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
An unidentified species of Theileria infective for cattle discovered in China. Trop Anim Health Prod (1997) 1.47
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol (1996) 1.47
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol (1999) 1.46
Chemotherapy for small cell carcinoma of prostatic origin. J Urol (1992) 1.46
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res (1995) 1.44
A developmental switch in neurotransmitter flux enhances synaptic efficacy by affecting AMPA receptor activation. Neuron (2001) 1.44
Net primary productivity of China's terrestrial ecosystems from a process model driven by remote sensing. J Environ Manage (2007) 1.43
Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res (2001) 1.43
Genetic evaluation of suspected cases of transient HIV-1 infection of infants. Science (1998) 1.43
Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Am Heart J (1998) 1.43
Complete heart block and sudden death in mice overexpressing calreticulin. J Clin Invest (2001) 1.43
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
FK506 in the treatment of children with nephrotic syndrome of different pathological types. Clin Nephrol (2006) 1.42
The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am (1998) 1.40
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol (2009) 1.40
Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene (2009) 1.40
Efficacy of colony-stimulating factors in acute leukemia. Ann Pharmacother (2001) 1.39
Effect of 24-h blood pressure levels and circadian blood pressure rhythm on left ventricular structure and function in isolated systolic hypertension. Int J Cardiol (1994) 1.39
Proline inhibits aggregation during protein refolding. Protein Sci (2000) 1.38
Zinc abuse and sideroblastic anemia. Am J Hematol (1993) 1.38
Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer. Cancer Invest (2000) 1.37
Effect of perfusion pressure on the splanchnic circulation after CPB: a pilot study. Minerva Anestesiol (2014) 1.37
Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chem Biol (1997) 1.35
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst (1997) 1.35
Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g. J Pediatr (2000) 1.34